Wells Fargo & Company Issues Pessimistic Forecast for Septerna (NASDAQ:SEPN) Stock Price

Septerna (NASDAQ:SEPN) had its price objective decreased by Wells Fargo & Company from $14.00 to $11.00 in a research report sent to investors on Friday morning,Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the stock.

Separately, Cantor Fitzgerald reiterated an “overweight” rating and set a $50.00 target price on shares of Septerna in a report on Tuesday, February 11th.

Septerna Stock Down 3.0 %

Shares of NASDAQ SEPN opened at $6.10 on Friday. Septerna has a 52-week low of $4.17 and a 52-week high of $28.99. The company has a 50 day moving average price of $9.96.

Septerna (NASDAQ:SEPN) last issued its earnings results on Thursday, March 27th. The company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.05. The firm had revenue of $0.21 million during the quarter, compared to analysts’ expectations of $0.13 million. Analysts anticipate that Septerna will post -7.11 EPS for the current year.

Insider Activity

In other news, CFO Gil M. Labrucherie purchased 10,500 shares of the firm’s stock in a transaction on Wednesday, February 19th. The stock was acquired at an average cost of $5.51 per share, with a total value of $57,855.00. Following the completion of the transaction, the chief financial officer now owns 10,500 shares in the company, valued at $57,855. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Alan Ezekowitz acquired 41,355 shares of the business’s stock in a transaction dated Thursday, March 6th. The stock was purchased at an average cost of $6.00 per share, for a total transaction of $248,130.00. Following the transaction, the director now owns 104,101 shares in the company, valued at approximately $624,606. The trade was a 65.91 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 74,346 shares of company stock worth $439,670.

Hedge Funds Weigh In On Septerna

Large investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC purchased a new position in Septerna during the 4th quarter worth $25,000. New York State Common Retirement Fund acquired a new stake in Septerna in the fourth quarter worth about $32,000. Legal & General Group Plc purchased a new stake in shares of Septerna during the fourth quarter worth about $42,000. Summit Investment Advisors Inc. purchased a new position in shares of Septerna in the 4th quarter valued at approximately $45,000. Finally, BNP Paribas Financial Markets purchased a new position in shares of Septerna in the 4th quarter valued at approximately $52,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.